Your browser doesn't support javascript.
loading
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.
Odegard, Jared M; Othman, Ahmed A; Lin, Kai-Wen; Wang, Adele Y; Nazareno, Jonathan; Yoon, Oh Kyu; Ling, John; Lad, Latesh; Dunbar, P Rod; Thai, Dung; Ang, Edmond; Waldron, Nicholas; Deva, Sanjeev.
Afiliación
  • Odegard JM; Biomarker Sciences, Gilead Sciences Inc, Seattle, Washington, USA jared.odegard@gmail.com.
  • Othman AA; Clinical Pharmacology, Gilead Sciences Inc, Foster City, California, USA.
  • Lin KW; Gilead Sciences, Inc, Foster City, California, USA.
  • Wang AY; Gilead Sciences, Inc, Foster City, California, USA.
  • Nazareno J; Gilead Sciences, Inc, Foster City, California, USA.
  • Yoon OK; Gilead Sciences, Inc, Foster City, California, USA.
  • Ling J; Gilead Sciences, Inc, Foster City, California, USA.
  • Lad L; Gilead Sciences, Inc, Foster City, California, USA.
  • Dunbar PR; School of Biological Sciences and Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Thai D; Gilead Sciences, Inc, Foster City, California, USA.
  • Ang E; University of Auckland, Auckland, New Zealand.
  • Waldron N; University of Auckland, Auckland, New Zealand.
  • Deva S; University of Auckland, Auckland, New Zealand.
J Immunother Cancer ; 12(4)2024 Apr 11.
Article en En | MEDLINE | ID: mdl-38604815

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos